Curis Regains Nasdaq Compliance After Reverse Split, But Faces Strict One-Year Monitor
CRIS sits 37% above its 52-week low of $3.612 on light trading volume (0.4× avg).
Summary
Curis regained Nasdaq compliance on July 24, 2026, following its reverse stock split, but is now under a strict one-year monitor where any new deficiency leads to immediate delisting proceedings.
Key Events · Legal and Risk Events · CRIS
-
Nasdaq Compliance Restored
On July 24, 2026, Curis received written notice from Nasdaq confirming it has regained compliance with the Bid Price Rule, following the 1-for-20 reverse stock split.
-
One-Year Discretionary Panel Monitor
The company is now subject to a Discretionary Panel Monitor for one year. Any new listing deficiency during this period will result in an immediate Delist Determination Letter, with no opportunity for a compliance plan or extension.
-
No Grace Period for Future Deficiencies
Under the monitor, Curis cannot submit a plan of compliance for any new deficiency, and Nasdaq staff cannot grant additional time to regain compliance — a hearing is the only recourse.
-
Going-Concern Risk Persists
The compliance restoration does not address Curis's underlying financial distress: a going-concern warning, no revenue, and a cash runway that remains tight.
Analysis · CRIS · Life Sciences
The immediate delisting threat is off the table: Curis has regained compliance with Nasdaq's bid price rule, a direct result of the 1-for-20 reverse stock split executed earlier this month. Yet the relief comes with a catch — the company now operates under a one-year Discretionary Panel Monitor. Any new listing deficiency during this period triggers an automatic delisting determination, with no grace period or compliance plan option. For a firm carrying a going-concern warning, no revenue, and a market cap under $10 million, this monitor period is a tightrope. The compliance restoration is positive, but the stringent monitoring underscores the fragility of Curis's listing status.
How filings like this one have moved
In the 30 days to Oct 5, 2026, 36.9% of the 964 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.65%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, CRIS was trading at $4.96 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $9.7M. The 52-week trading range was $3.61 to $39.00. This filing was assessed with neutral market sentiment and an importance score of 8 out of 10.